抗憂鬱症市場（按藥物類別、給藥途徑、分銷管道和地區分類）

預計 2025 年全球抗憂鬱症市場規模為 201.1 億美元，到 2032 年將達到 331.6 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 7.4%。

數字。 2025年抗憂鬱症市場佔有率（按地區分列）

抗憂鬱症是用於治療重度憂鬱症的藥物。它用於改變大腦化學反應，以緩解悲傷、失去興趣、內疚感或低自我價值感、睡眠問題或食慾不振、疲勞和注意力不集中等症狀。憂鬱症和其他精神疾病的盛行率不斷提高，人們對此的認知不斷提高，這加劇了全球對抗抗憂鬱症的需求。此外，大型製藥企業對新型先進治療方法的開發也推動了市場的成長。然而，替代治療方法的可用性以及抗憂鬱症的副作用在一定程度上限制了市場擴張。

市場動態：

影響全球抗憂鬱症市場成長的市場促進因素包括憂鬱症和其他精神疾病盛行率的上升、對憂鬱症診斷和管理的認知的提高、新產品的推出以及醫療保健支出的增加。根據世界衛生組織估計，全球有超過2.64億人患有憂鬱症。以身心障礙生活年資（YLD）衡量，憂鬱症也是導致失能的主要原因。此外，抗憂鬱症用於治療憂鬱症以外的其他疾病（如焦慮症、創傷後壓力症候群 (PTSD)、月經煩躁症 (PMDD) 和慢性疼痛）的接受度不斷提高，也推動了市場的成長。然而，心理治療、電痙攣療法和社會支持等替代治療方法的出現，限制了全球對抗抗憂鬱症的完全依賴。此外，許多人在使用抗憂鬱症後會出現輕微至嚴重的副作用，包括失眠、性功能障礙、體重變化、胃腸道問題和頭痛，這限制了藥物的依從性和整體市場收益。新型抗憂鬱症的高成本也阻礙了市場發展，特別是在對價格敏感的開發中國家。學名藥開發為滿足預算受限的消費者的未滿足需求提供了機會。

本研究的主要特點

本報告對全球抗憂鬱症市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模（以十億美元為單位）和年複合成長率（CAGR%）。

它還強調了各個領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。

它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球抗憂鬱症市場的主要企業概況。

研究涉及的主要企業包括輝瑞、禮來、Astra Zeneca、GlaxoSmithKline Plc和諾華。

本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

全球抗憂鬱症市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過用於分析全球抗憂鬱症市場的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 主要進展
• 監管情景
• 收購與合作場景
• 資金籌措與投資
• PEST分析
• 波特分析

4. 全球抗憂鬱症市場-COVID-19 疫情的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2021-2032 年全球抗憂鬱症市場（依藥物類別）

• 選擇性血清素再回收抑制劑（SSRI）
• Fluoxetine
• 舍曲林
• 其他
• 正腎上腺素再回收抑制劑（SNRI）
• 文拉法辛
• Duloxetine
• 其他
• 三環抗憂鬱藥物（TCA）
• 阿米替林
• 丙咪嗪
• 其他
• 單胺氧化酵素抑制劑（MAOI）
• 苯乙肼
• 反苯環丙胺
• 其他
• 非典型抗憂鬱症
• 安非他酮
• 曲唑酮
• 其他

6. 全球抗憂鬱症市場（依給藥途徑分類），2021-2032 年

• 口服
• 皮下
• 靜脈
• 其他

7. 全球抗憂鬱症市場（依通路分類），2021-2032 年

• 醫院藥房
• 零售藥局
• 網路藥局

8. 2021-2032 年全球抗憂鬱症市場（按地區）

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章競爭格局

• 公司簡介
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson &Johnson
  • H. Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

第 10 章分析師建議

• 命運之輪
• 分析師觀點
• 一致的機會圖

第11章調查方法

• 參考
• 調查方法

Global Antidepressant Market is estimated to be valued at USD 20.11 Bn in 2025 and is expected to reach USD 33.16 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

Figure. Antidepressant Market Share (%), By Region 2025

Antidepressants are medications prescribed to treat major depressive disorders. They are used to alter brain chemistry in order to relieve symptoms such as sadness, loss of interest, feelings of guilt or low self-worth, disturbed sleep or appetite, fatigue, and poor concentration. The increasing prevalence of depression and other mental health disorders along with growing awareness is fueling the demand for antidepressants globally. Moreover, development of new and advanced treatment options by major pharmaceutical companies is also boosting market growth. However, availability of alternative treatment methods and side-effects associated with antidepressant drugs restrict the market expansion to some extent.

Market Dynamics:

The drivers influencing growth of global antidepressant market include rising incidence of depression and other mental health conditions, growing awareness about depression diagnosis and management, new product launches, and increasing expenditure on healthcare. According to WHO, over 264 million people are estimated to suffer from depression worldwide. Depression is also the leading cause of disability as measured by Years Lived with Disability (YLDs). Furthermore, growing acceptance of antidepressants for conditions other than depression such as anxiety disorders, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and chronic pain is driving their market growth. However, availability of alternative treatment methods such as psychotherapy, electroconvulsive therapy, and social support is restricting complete reliance on antidepressants globally. Also, many individuals experience mild to serious side-effects such as insomnia, sexual dysfunction, weight changes, gastrointestinal issues, and headaches with antidepressant use, which limits their compliance and overall market revenue. High costs of new antidepressants also hinder the market growth, especially in price-sensitive developing nations. Development of generics offers opportunities to address the unmet needs of consumers with budget constraints.

Key features of the study:

This report provides in-depth analysis of the global antidepressant market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 s the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global antidepressant market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, AstraZeneca, GlaxoSmithKline, and Novartis

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global antidepressant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antidepressant market

Detailed Segmentation-

• By Drug Class
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Fluoxetine
  • Sertraline
  • Others
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Venlafaxine
  • Duloxetine
  • Others
  • Tricyclic Antidepressants (TCAs)
  • Amitriptyline
  • Imipramine
  • Others
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Phenelzine
  • Tranylcypromine
  • Others
  • Atypical Antidepressants
  • Bupropion
  • Trazodone
  • Others
• By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
• By Distribution Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson
  • Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Antidepressant Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Antidepressant Market, By Drug Class, 2021 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fluoxetine
• Sertraline
• Others
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Venlafaxine
• Duloxetine
• Others
• Tricyclic Antidepressants (TCAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Amitriptyline
• Imipramine
• Others
• Monoamine Oxidase Inhibitors (MAOIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phenelzine
• Tranylcypromine
• Others
• Atypical Antidepressants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bupropion
• Trazodone
• Others

6. Global Antidepressant Market, By Route of Administration, 2021 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Antidepressant Market, By Distribution Channel, 2021 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Antidepressant Market, By Region, 2021 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Eli Lilly and Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Market Strategies
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson
  • H. Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Research Methodology

• References
• Research Methodology
• About us and Sales Contact